A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
about
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestJanus kinase inhibitors in autoimmune diseasesShared epitope-antagonistic ligands: a new therapeutic strategy in mice with erosive arthritis.HCV infection enhances Th17 commitment, which could affect the pathogenesis of autoimmune diseases.Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Back to the future: oral targeted therapy for RA and other autoimmune diseases.Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis.Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen.Kinase inhibitors in the treatment of immune-mediated diseaseJAK and STAT signaling molecules in immunoregulation and immune-mediated disease.The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells.JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsTherapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Investigational drugs for treating psoriatic arthritis.New pharmacotherapy options for noninfectious posterior uveitis.Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis.JAK2 inhibitor CEP-33779 prevents mouse oocyte maturation in vitro.STAT1 expression and activation is increased in lesional psoriatic skin.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.5,7,3'-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway.Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations.The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis.
P2860
Q24617270-17831BA9-29FC-4E1E-BE15-ECEEA3980606Q26774874-B1D6DF24-71BD-41B7-A289-0094018EEFA4Q26777398-EE3790BB-6B82-4042-9DA3-AD8811FA64F7Q26865446-B87C5EBA-D21C-4752-98AE-4EF5F3200D73Q27339594-01CC24E5-7FD6-40B6-B5CF-240EABDDAAF6Q33721367-308AFA5E-30C0-432B-BA6F-D7A7ACEF3544Q33988247-D87E00FB-6E8A-40B2-83BC-99A9C7A9A0ECQ34213332-EAC219D2-A26E-41E8-AC92-04CA2621855DQ34423091-1957EF48-FD52-4034-91FB-D300C64105BCQ35553626-69139F2A-379A-487E-A577-08C87AAE1F66Q35814037-A2BC545C-1AEB-4F71-AC71-21BA235BF7E2Q36404704-29B2F2A7-4817-46AE-9772-1373ACC57565Q37039005-742DA5D1-49FC-46B2-BD04-2756E32542B1Q37168138-0CCAD364-3F90-4F21-89E6-5A71F18CA0F7Q37603419-764A2CC8-B7E1-4C7A-9911-D7B5117FA60AQ38042734-E984DD37-A9E7-4538-B81F-C26374CB03C7Q38203779-D6124BF3-B52B-449D-8374-25CBFD83BC2FQ38206551-648D7015-1476-4829-B6A9-4C3BC2FF11DCQ38253095-03447925-3135-4BEB-902C-16F9DEDA5644Q39024059-312E84ED-7DCA-4B18-813C-BDE48C6B2290Q42334834-09304BB5-8971-42C6-BC55-19E008C00ADEQ46903707-10B15EA1-B1F8-4D12-BD84-683B4799BD33Q48109284-8E68AC02-75AD-4E47-BB5E-5BAE99D66B33Q50957785-ADF60C85-6BAE-4697-BFBA-93C592626CB0Q50984592-528FBC9F-8B6E-43E1-AD18-2AA5A78D59E4Q55631301-3B738514-8EF9-4A2E-A07B-FA3E98AE3358
P2860
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A highly selective, orally act ...... odels of rheumatoid arthritis.
@ast
A highly selective, orally act ...... odels of rheumatoid arthritis.
@en
type
label
A highly selective, orally act ...... odels of rheumatoid arthritis.
@ast
A highly selective, orally act ...... odels of rheumatoid arthritis.
@en
prefLabel
A highly selective, orally act ...... odels of rheumatoid arthritis.
@ast
A highly selective, orally act ...... odels of rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
A highly selective, orally act ...... odels of rheumatoid arthritis.
@en
P2093
Ben J Dugan
Bruce A Ruggeri
Bruce D Dorsey
Cynthia Serdikoff
Diane E Gingrich
Kristine L Stump
Mark A Ator
Mark S Albom
Matthew M Seavey
P2860
P2888
P356
10.1186/AR3329
P577
2011-04-21T00:00:00Z
P5875
P6179
1036803458